These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 20042718)

  • 1. Designing early detection programs for ovarian cancer.
    Hartge P
    J Natl Cancer Inst; 2010 Jan; 102(1):3-4. PubMed ID: 20042718
    [No Abstract]   [Full Text] [Related]  

  • 2. Assessing lead time of selected ovarian cancer biomarkers: a nested case-control study.
    Anderson GL; McIntosh M; Wu L; Barnett M; Goodman G; Thorpe JD; Bergan L; Thornquist MD; Scholler N; Kim N; O'Briant K; Drescher C; Urban N
    J Natl Cancer Inst; 2010 Jan; 102(1):26-38. PubMed ID: 20042715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125.
    Shah CA; Lowe KA; Paley P; Wallace E; Anderson GL; McIntosh MW; Andersen MR; Scholler N; Bergan LA; Thorpe JD; Urban N; Drescher CW
    Cancer Epidemiol Biomarkers Prev; 2009 May; 18(5):1365-72. PubMed ID: 19423517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of personal characteristics on serum CA125, mesothelin, and HE4 levels in healthy postmenopausal women at high-risk for ovarian cancer.
    Lowe KA; Shah C; Wallace E; Anderson G; Paley P; McIntosh M; Andersen MR; Scholler N; Bergan L; Thorpe J; Urban N; Drescher CW
    Cancer Epidemiol Biomarkers Prev; 2008 Sep; 17(9):2480-7. PubMed ID: 18768519
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HE4 and mesothelin: novel biomarkers of ovarian carcinoma in patients with pelvic masses.
    Abdel-Azeez HA; Labib HA; Sharaf SM; Refai AN
    Asian Pac J Cancer Prev; 2010; 11(1):111-6. PubMed ID: 20593939
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a multimarker assay for early detection of ovarian cancer.
    Yurkovetsky Z; Skates S; Lomakin A; Nolen B; Pulsipher T; Modugno F; Marks J; Godwin A; Gorelik E; Jacobs I; Menon U; Lu K; Badgwell D; Bast RC; Lokshin AE
    J Clin Oncol; 2010 May; 28(13):2159-66. PubMed ID: 20368574
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Potential role of HE4 in multimodal screening for epithelial ovarian cancer.
    Urban N; Thorpe JD; Bergan LA; Forrest RM; Kampani AV; Scholler N; O'Briant KC; Anderson GL; Cramer DW; Berg CD; McIntosh MW; Hartge P; Drescher CW
    J Natl Cancer Inst; 2011 Nov; 103(21):1630-4. PubMed ID: 21917606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness of serum HE4 in endometriotic cysts.
    Montagnana M; Lippi G; Danese E; Franchi M; Guidi GC
    Br J Cancer; 2009 Aug; 101(3):548. PubMed ID: 19513069
    [No Abstract]   [Full Text] [Related]  

  • 9. A step forward for two-step screening for ovarian cancer.
    Hensley ML
    J Clin Oncol; 2010 May; 28(13):2128-30. PubMed ID: 20368556
    [No Abstract]   [Full Text] [Related]  

  • 10. SMRP and HE4 as biomarkers for ovarian carcinoma when used alone and in combination with CA125 and/or each other.
    Hellstrom I; Hellstrom KE
    Adv Exp Med Biol; 2008; 622():15-21. PubMed ID: 18546615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fujirebio Diagnostics to develop new markers for the early detection of ovarian cancer.
    Expert Rev Mol Diagn; 2002 Sep; 2(5):401-2. PubMed ID: 12271811
    [No Abstract]   [Full Text] [Related]  

  • 12. Advances in the early detection of ovarian cancer: How to hear the whispers early.
    Cesario S
    Nurs Womens Health; 2010 Jun; 14(3):222-34. PubMed ID: 20579298
    [No Abstract]   [Full Text] [Related]  

  • 13. Potential markers that complement expression of CA125 in epithelial ovarian cancer.
    Rosen DG; Wang L; Atkinson JN; Yu Y; Lu KH; Diamandis EP; Hellstrom I; Mok SC; Liu J; Bast RC
    Gynecol Oncol; 2005 Nov; 99(2):267-77. PubMed ID: 16061277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass.
    Moore RG; McMeekin DS; Brown AK; DiSilvestro P; Miller MC; Allard WJ; Gajewski W; Kurman R; Bast RC; Skates SJ
    Gynecol Oncol; 2009 Jan; 112(1):40-6. PubMed ID: 18851871
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Screening for Ovarian Cancer with CA 125 and Ultrasound Algorithm Does Not Reduce Mortality.
    Ebell MH
    Am Fam Physician; 2021 Oct; 104(4):422-423. PubMed ID: 34652113
    [No Abstract]   [Full Text] [Related]  

  • 16. Progress report on ovarian cancer screening. Scientists are making headway in detecting ovarian cancer at an earlier stage.
    Harv Womens Health Watch; 2010 Apr; 17(8):1-3. PubMed ID: 20506601
    [No Abstract]   [Full Text] [Related]  

  • 17. Bead-based ELISA for validation of ovarian cancer early detection markers.
    Scholler N; Crawford M; Sato A; Drescher CW; O'Briant KC; Kiviat N; Anderson GL; Urban N
    Clin Cancer Res; 2006 Apr; 12(7 Pt 1):2117-24. PubMed ID: 16609024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The utility of human epididymal protein 4, cancer antigen 125, and risk for malignancy algorithm in ovarian cancer and endometriosis.
    Kadija S; Stefanovic A; Jeremic K; Radojevic MM; Nikolic L; Markovic I; Atanackovic J
    Int J Gynecol Cancer; 2012 Feb; 22(2):238-44. PubMed ID: 22214964
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The early detection of ovarian cancer: from traditional methods to proteomics. Can we really do better than serum CA-125?
    Nossov V; Amneus M; Su F; Lang J; Janco JM; Reddy ST; Farias-Eisner R
    Am J Obstet Gynecol; 2008 Sep; 199(3):215-23. PubMed ID: 18468571
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HE4 as a biomarker for ovarian and endometrial cancer management.
    Li J; Dowdy S; Tipton T; Podratz K; Lu WG; Xie X; Jiang SW
    Expert Rev Mol Diagn; 2009 Sep; 9(6):555-66. PubMed ID: 19732003
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.